Date Document
29/11/2021 Jobkeeper Announcement
25/11/2021 Results of Meeting
25/11/2021 Investor Presentation - Positioning for Growth
24/11/2021 Appointment of CMO - Professor John Olynyk
23/11/2021 ASO R&D Project - Filing of Two Patent Applications
12/11/2021 Thalassaemia International Federation to Deploy FerriSmart
29/10/2021 Quarterly Activities/Appendix 4C Cash Flow Report
25/10/2021 Notice of Annual General Meeting/Proxy Form
14/10/2021 Sales & Marketing Update
13/10/2021 New AI Medical Device
07/10/2021 AGM Date and Director Nomination Closing Date
30/09/2021 Appendix 4G and Corporate Governance Statement
30/09/2021 Annual Report to shareholders
28/09/2021 Change in substantial holding
21/09/2021 R&D Molecular Medicine ASON Project Results of Dosing Study
30/08/2021 Preliminary Final Report
02/08/2021 Quarterly Activities/Appendix 4C Cash Flow Report
28/07/2021 Appointment of GM - Global Sales & Marketing
01/07/2021 Change of Director's Interest Notice
01/07/2021 Cancellation of Unlisted Options
30/06/2021 Controlled Placement Facility - Extension and Increase
28/06/2021 Change of Director's Interest Notice
28/06/2021 Appointment of Managing Director
11/06/2021 Secondary Trading Notice
11/06/2021 Application for quotation of securities - RHT
04/06/2021 Resignation of CEO & Management Changes
24/05/2021 Filing of Patent Application
17/05/2021 R&D Update - Molecular Medicine ASO Project
29/04/2021 Appendix 4C - quarterly
08/04/2021 Appointment of CFO & Company Secretary
09/03/2021 Change of Director's Interest Notice
09/03/2021 Secondary Trading Notice & Appendix 2A
26/02/2021 Half Yearly Report and Accounts
24/02/2021 HepaFat-AI receives CE Marking
18/02/2021 HepaFat-AI Receives TGA Approval
17/02/2021 Trading Halt
17/02/2021 Pause in Trading
28/01/2021 Appendix 4C - quarterly
12/01/2021 Secondary Trading Notice & Appendix 2A